Is Australian Pharmaceutical Industries Ltd a post earnings buy?

The Australian Pharmaceutical Industries Ltd (ASX: API)  share price has fallen over 6% to $1.41 after the release of its half-yearly for the period ended 28 February 2018 yesterday.

The stock has now lost 31% over the last 12 months as the company faces an increasingly difficult operating environment in its Priceline retail stores network and pharmacy distribution business.

Flat revenue and declining profitability

Revenue for the group was essentially flat, dropping 0.3% to $2.0 billion for the period. Retail register sales from Priceline fell by 0.3% to $593 million despite the number of network stores increasing to 466 from 450 in the prior corresponding period.

This resulted in comparable store sales shrinking by 1.7% as the company’s retail arm struggles with a subdued Australian consumer battling low wages growth and high utility bills.

Pharmacy distribution revenue was 0.3% lower to $1.45 billion and was negatively impacted by reduced demand for high cost Hepatitis C medicines as also seen in rival Sigma Healthcare Limited (ASX: SIG).

Eliminating the impact from the Hepatitis C reduction and Pharmaceutical Benefits Scheme (PBS) reforms resulted in underlying sales growth being 9.8% higher than the prior period, underpinned by gains from independent pharmacies.

After backing out a $2.6 million adjustment related to business restructuring and strategic business growth, underlying net profit after tax for the group fell 8.1% to $26.8 million with underlying earnings per share decreasing 10% to 5.4 cents. Management expects the company’s FY18 underlying result to be marginally above its FY17 result under the assumption that current trading conditions do not worsen. 

Foolish takeaway

This was a result roughly in line with the expectations management outlined at the company’s AGM in January. Given the current issues in the Australian retail and pharmacy distribution segments it is difficult to build a compelling bullish thesis for the company in the near term. The company’s largest shareholder, Washington H. Soul Pattinson and Co. Ltd  (ASX: SOL),  notably decreased its ownership interest in the business last year.

However, one thing to watch out for is the possibility of Australian Pharmaceutical Industries taking over Sigma Healthcare’s wholesale supply contract for the My Chemist/Chemist Warehouse Group which ends in June 2019 and is up for tender. 

Breaking news: ASX companies set to raise dividends!

It's been a nail-biter of a reporting season here in the first half of 2018.

But the real action, in my opinion, is what companies are doing with dividends.

What does this mean for you? Well there is one stock I've found that could very well turn out to be THE best buy of 2018. And while there's no such thing as a 'sure thing' when it comes to investing - this ripper might come as close as I've ever seen.

Click here it's FREE!

Motley Fool contributor Tim Katavic has no financial interest in any company mentioned. The Motley Fool Australia owns shares of and has recommended Washington H. Soul Pattinson and Company Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!